INTI — Inhibitor Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $6.90m
- $3.17m
Annual balance sheet for Inhibitor Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.075 | 0.031 | 12 | 8.84 | 5.61 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.107 | 0.059 | 12 | 8.95 | 5.69 |
| Other Long Term Assets | |||||
| Total Assets | 0.132 | 0.059 | 12 | 8.95 | 5.69 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.425 | 0.68 | 0.679 | 0.665 | 0.71 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.49 | 3.68 | 3.68 | 3.67 | 3.71 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -3.36 | -3.62 | 8.3 | 5.28 | 1.99 |
| Total Liabilities & Shareholders' Equity | 0.132 | 0.059 | 12 | 8.95 | 5.69 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |